Novartis

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Novartis and other ETFs, options, and stocks.

About NVS

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate.

CEO

Vasant Narasimhan

CEOVasant Narasimhan

Employees

104,323

Employees104,323

Headquarters

Basel, Basel-Stadt (Basle Town)

HeadquartersBasel, Basel-Stadt (Basle Town)

Founded

1996

Founded1996

Employees

104,323

Employees104,323

NVS Key Statistics

Market cap

215.69B

Market cap215.69B

Price-Earnings ratio

9.48

Price-Earnings ratio9.48

Dividend yield

2.33

Dividend yield2.33

Average volume

2.02M

Average volume2.02M

High today

$91.30

High today$91.30

Low today

$89.42

Low today$89.42

Open price

$90.98

Open price$90.98

Volume

2.67M

Volume2.67M

52 Week high

$94.26

52 Week high$94.26

52 Week low

$74.09

52 Week low$74.09

NVS News

Benzinga 2d

Sandoz Acquires Antifungal Agent From Astellas, Reinforcing Hospital Offering

In this article: Sandoz , a generic pharmaceuticals and biosimilar unit of Novartis AG (NYSE: NVS), has agreed to acquire worldwide product rights for systemic...

Yahoo Finance 3d

Sandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolio - Yahoo Finance

Sandoz plans to acquire worldwide product rights for Mycamine ® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three major ant...

Yahoo Finance 4d

Those who invested in Novartis a year ago are up 15% - Yahoo Finance

The simplest way to invest in stocks is to buy exchange traded funds. But one can do better than that by picking better than average stocks (as part of a divers...

Analyst ratings

56%

of 27 ratings

Buy

33.3%

Hold

55.6%

Sell

11.1%

NVS Earnings

$0.00

$0.57

$1.14

$1.71

Q2 FY21

Q3 FY21

Q4 FY21

Q1 FY22

Q2 FY22

Q3 FY22

Q4 FY22

Estimated

$1.39 per share

Estimated$1.39 per share

Actual

Available Feb 1, Pre-Market

ActualAvailable Feb 1, Pre-Market